Abstract: A drug containing a metal-salen complex compound which is effective for a brain tumor is provided. The present invention is an anti-brain-tumor drug containing a metal-salen complex compound represented by the following Chemical Formula (I). In the formula, M represents a metal atom which is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd, and X represents a halogen atom.

Abstract: It is an object of the present invention to extend the usefulness of an iron-salen complex. The present invention is a new fluorochrome material containing Chemical Formula (I) below. However, M is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd.

Abstract: A metal-salen complex derivative with an excellent yield and stability is provided and a method for producing such a metal-salen complex derivative is provided. The present invention provides: metal-salen complex derivative obtained by allowing a target component composed of at least one of an enzyme, an antibody, an antigen, a peptide, an amino acid, an oligonucleotide, a protein, a nucleic acid, and a medical molecule to bind to a metal-salen complex via an amide bond or a disulfide bond; a method for producing such a metal-salen complex derivative.

Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.

Abstract: A magnetic body may be suitably applied to a drug delivery system using magnetism. Furthermore, a drug delivery control device allows the magnetic body to be suitably applied to drug delivery. The magnetic body includes a magnet and a cover part attached to an edge of the magnet. The cover part is composed of a material with high magnetic permeability, and a ratio of a length to a radius of the cover part is 10:1 to 7:3. The drug delivery control device includes the magnetic body, a head for supporting the magnetic body and a drive mechanism of the head that causes the head to operate along a projected region formed by the affected area with respect to a surface of a tissue. A magnetic field is applied from the magnetic body to the affected area where a magnetic drug is administered.

Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.

Abstract: A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. The drug can be delivered to the diseased site using the magnetic properties of the drug per se without using a carrier made of a magnetic substance as in the conventional methods.

Abstract: A method for evaluating the binding of an evaluation target molecule with respect to a macromolecular compound based on numerical calculations and which detects the binding sites of the evaluation target molecule with respect to the macromolecular compound as a site where electronic states in a predetermined restricted region including the evaluation target molecule and the part of the macromolecular compound, which is adjacent to the evaluation target molecule, are unstable.

Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.

Abstract: A drug comprises an organic or inorganic compound, and is made magnetic by modification of side chains and/or crosslinking between side chains.

Abstract: The present invention provides a drug delivery system that overcomes conventional technical problems and that is readily put to practical use. Iron-salen complexes represented by General Formula (I) below. The invention renders iron-salen complexes magnetic, which can thus be used as drugs that can be delivered to affected areas in the body using the inherent magnetic properties of the drug without employing carriers composed of magnetic substances as has been done hitherto.

Abstract: In an activity evaluation method for an evaluation target compound, among atoms constituting the evaluation target compound, one or more are set as analysis points, and an activity of the evaluation target compound with respect to a high molecular compound is calculated based on a predetermined evaluation expression having Fukui function values as variables obtained by numerical calculation for the set analysis points.

Abstract: A method for evaluating the binding of an evaluation target molecule with respect to a macromolecular compound based on numerical calculations and which detects the binding sites of the evaluation target molecule with respect to the macromolecular compound as a site where electronic states in a predetermined restricted region including the evaluation target molecule and the part of the macromolecular compound, which is adjacent to the evaluation target molecule, are unstable.

Abstract: In an activity evaluation method for an evaluation target compound, among atoms constituting the evaluation target compound, one or more are set as analysis points, and an activity of the evaluation target compound with respect to a high molecular compound is calculated based on a predetermined evaluation expression having Fukui function values as variables obtained by numerical calculation for the set analysis points.

Abstract: In high-tech fields such as electronics, the development of new high performance materials which differ from conventional materials has received much attention. An object of the present invention is to provide a clathrate compound which can be used as a thermoelectric material, a hard material, or a semiconductor material. Atoms of an element from group 4B of the periodic table are formed into a clathrate lattice, and a clathrate compound is then formed in which specified doping atoms are encapsulated within the clathrate lattice, and a portion of the atoms of the clathrate lattice are substituted with specified substitution atoms. Suitable doping atoms are atoms from group 1A, group 2A, group 3A, group 1B, group 2B, group 3B, group 4A, group 5A, group 6A, and group 8, and suitable substitution atoms are atoms from group 1A, group 2A, group 3A, group 1B, group 2B, group 3B, group 5A, group 6A, group 7A, group 5B, group 6B, group 7B, and group 8 of the periodic table.

Abstract: In high-tech fields such as electronics, the development of new high performance materials which differ from conventional materials has received much attention. An object of the present invention is to provide a clathrate compound which can be used as a thermoelectric material, a hard material, or a semiconductor material. Atoms of an element from group 4B of the periodic table are formed into a clathrate lattice, and a clathrate compound is then formed in which specified doping atoms are encapsulated within the clathrate lattice, and a portion of the atoms of the clathrate lattice are substituted with specified substitution atoms. Suitable doping atoms are atoms from group 1A, group 2A, group 3A, group 1B, group 2B, group 3B, group 4A, group 5A, group 6A, and group 8, and suitable substitution atoms are atoms from group 1A, group 2A, group 3A, group 1B, group 2B, group 3B, group 5A, group 6A, group 7A, group 5B, group 6B, group 7B, and group 8 of the periodic table.

Abstract: The present invention provides a clathrate compound which can be used as a thermoelectric material, a hard material, or a semiconductor material. Silicon or carbon are formed into a clathrate lattice, and a clathrate compound is then formed in which specified doping atoms are encapsulated within the clathrate lattice, and a portion of the atoms of the clathrate lattice are substituted with specified substitution atoms. The clathrate lattice is, for example, a silicon clathrate 34 (Si34) mixed lattice of a Si20 cluster including a dodecahedron of Si atoms, and a Si28 cluster including a hexahedron of Si atoms. Suitable doping atoms are atoms from group 1A, group 2A, group 3A, group 1B, group 2B, group 3B, group 4A, group 5A, group 6A, and group 8, and suitable substitution atoms are atoms from group 1A, group 2A, group 3A, group 1B, group 2B, group 3B, group 5A, group 6A, group 7A, group 5B, group 6B, group 7B, and group 8 of the periodic table.

Abstract: In a camera having a lens unit and a viewfinder, a power focus limiter is provided which is capable of narrowing the focusing range by using a driving motor. The device consists of an actuator, a motor control circuit, a driving motor and a detecting sensor, and a display device that provides a visual reference of the focusing range presently set to the operator. The system allows the focusing range to narrow quickly, while at the same time the operator can confirm whether the focusing range is in the desired range without moving his eye from the viewfinder.

Abstract: A lens barrel attachment including an attachment ring and a handle in which a click pin is housed. The attachment ring is rotatably fitted on a large-sized lens barrel. The handle is threadingly fitted in a handle hole formed in the attachment ring and extending in a radial direction thereof. The click pin is provided in an accommodation hole formed in the handle and urged by a spring to be engaged with engaging recesses formed on an outer surface of the lens barrel. The handle has a contact portion at the tip portion thereof. This contact portion is brought into frictional contact with the lens barrel to thereby fix the lens barrel to the attachment ring.

Abstract: A lens barrel for an automatic focusing camera is provided with an annular changeover member arranged so as to be manually rotatable about the optical axis, and further arranged so as to be manually movable in a direction of the optical axis. A first clutch mechanism is provided for releasing a connection between the annular changeover member and an annular focusing member, to permit independent rotation thereof, when the annular changeover member is in an AF mode setting position, and for forming the connection therebetween to thereby form a rotationally dependent structure when it is in an MF mode setting position. A second clutch mechanism is provided for forming a connection between a drive shaft and the annular focusing member when the annular changeover member is in the AF mode setting position, and for releasing the connection therebetween when it is in the MF mode setting position.